Tranexamic acid dosing for cardiac surgical patients with chronic renal dysfunction: A new dosing regimen

Anesthesia and Analgesia

Volumn 127, Issue 6, 2018, Pages 1323-1332

  Jerath, Angela ^a,b   Yang, Aqi Joy ^c   Pang, K Sandy ^c   Looby, Nikita ^d   Reyes Garces, Nathaly ^d   Vasiljevic, Tijana ^d   Bojko, Barbara ^d   Pawliszyn, Janusz ^d   Wijeysundera, Duminda ^a,b   Beattie, W Scott ^a,b   Yau, Terrence M ^a   Wasowicz, Marcin ^a,b  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF WATERLOO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; APROTININ; TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT;

ADULT; AGED; ARTICLE; BLOOD CONSERVATION; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; FIBRINOLYSIS; HEART SURGERY; HEART VALVE REPLACEMENT; HIGH RISK POPULATION; HOSPITAL MORTALITY; HOSPITALIZATION; HUMAN; KIDNEY DYSFUNCTION; LENGTH OF STAY; LOW RISK POPULATION; MALE; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PERIOPERATIVE PERIOD; PHARMACOKINETIC PARAMETERS; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEIZURE; SURGICAL PATIENT; SURGICAL RISK; THROMBOSIS; TREATMENT INDICATION; VALVULOPLASTY; VOLUME OF DISTRIBUTION; CARDIOPULMONARY BYPASS; CHRONIC KIDNEY FAILURE; DRUG ADMINISTRATION; HEALTH CARE QUALITY; ISCHEMIA; MIDDLE AGED; POSTOPERATIVE PERIOD; RISK; TREATMENT OUTCOME;

AGED; ANTIFIBRINOLYTIC AGENTS; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HOSPITAL MORTALITY; HUMANS; ISCHEMIA; LENGTH OF STAY; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; PROSPECTIVE STUDIES; QUALITY OF HEALTH CARE; RENAL INSUFFICIENCY, CHRONIC; RISK; SEIZURES; THROMBOSIS; TRANEXAMIC ACID; TREATMENT OUTCOME;

EID: 85056140187     PISSN: 00032999     EISSN: 15267598     Source Type: Journal    
DOI: 10.1213/ANE.0000000000002724     Document Type: Article

References (36)

1. Fergusson DA, Hébert PC, Mazer CD, et al; BART Investigators. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008;358:2319-2331.
2. Cooper WA, O'Brien SM, Thourani VH, et al. Impact of renal dysfunction on outcomes of coronary artery bypass surgery: results from the Society of Thoracic Surgeons National Adult Cardiac Database. Circulation. 2006;113:1063-1070.
3. Weiner DE, Tighiouart H, Stark PC, et al. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis. 2004;44:198-206.
4. Durmaz I, Büket S, Atay Y, et al. Cardiac surgery with cardiopulmonary bypass in patients with chronic renal failure. J Thorac Cardiovasc Surg. 1999;118:306-315.
5. Holzmann MJ, Hammar N, Ahnve S, Nordqvist T, Pehrsson K, Ivert T. Renal insufficiency and long-term mortality and incidence of myocardial infarction in patients undergoing coronary artery bypass grafting. Eur Heart J. 2007;28:865-871.
6. Witczak B, Hartmann A, Svennevig JL. Multiple risk assessment of cardiovascular surgery in chronic renal failure patients. Ann Thorac Surg. 2005;79:1297-1302.
7. Ferguson TB Jr, Hammill BG, Peterson ED, DeLong ER, Grover FL. A decade of change-risk profiles and outcomes for isolated coronary artery bypass grafting procedures, 1990-1999: a report from the STS National Database Committee and the Duke Clinical Research Institute. Society of Thoracic Surgeons. Ann Thorac Surg. 2002;73:480-490.
8. Ferraris VA, Brown JR, Despotis GJ, et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg. 2011;91:944-982.
9. Myles PS, Smith JA, Forbes A, et al; ATACAS Investigators of the ANZCA Clinical Trials Network. Tranexamic acid in patients undergoing coronary-artery surgery. N Engl J Med. 2017;376:136-148.
10. Sharma V, Fan J, Jerath A, et al. Pharmacokinetics of tranexamic acid in patients undergoing cardiac surgery with use of cardiopulmonary bypass. Anaesthesia. 2012;67:1242-1250.
11. Wasowicz M, Jerath A, Bojko B, Sharma V, Pawliszyn J, McCluskey S. Use of a novel technique, solid phase microextraction, to measure tranexamic acid in patients undergoing cardiac surgery. Can J Anaesth. 2012;59:14-20.
12. Sharma V, Katznelson R, Jerath A, et al. The association between tranexamic acid and convulsive seizures after cardiac surgery: a multivariate analysis in 11 529 patients. Anaesthesia. 2014;69:124-130.
13. Manji RA, Grocott HP, Leake J, et al. Seizures following cardiac surgery: the impact of tranexamic acid and other risk factors. Can J Anaesth. 2012;59:6-13.
14. Kalavrouziotis D, Voisine P, Mohammadi S, Dionne S, Dagenais F. High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass. Ann Thorac Surg. 2012;93:148-154.
15. Dowd NP, Karski JM, Cheng DC, et al. Pharmacokinetics of tranexamic acid during cardiopulmonary bypass. Anesthesiology. 2002;97:390-399.
16. Pilbrant A, Schannong M, Vessman J. Pharmacokinetics and bioavailability of tranexamic acid. Eur J Clin Pharmacol. 1981;20:65-72.
17. Andersson L, Eriksson O, Hedlund PO, Kjellman H, Lindqvist B. Special considerations with regard to the dosage of tranexamic acid in patients with chronic renal diseases. Urol Res. 1978;6:83-88.
18. Yang QJ, Jerath A, Bies RR, Wasowicz M, Pang KS. Pharmacokinetic modeling of tranexamic acid for patients undergoing cardiac surgery with normal renal function and model simulations for patients with renal impairment. Biopharm Drug Dispos. 2015;36:294-307.
19. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):S1-S266.
20. Goobie SM, Meier PM, Sethna NF, et al. Population pharmacokinetics of tranexamic acid in paediatric patients undergoing craniosynostosis surgery. Clin Pharmacokinet. 2013;52:267-276.
21. Grassin-Delyle S, Couturier R, Abe E, Alvarez JC, Devillier P, Urien S. A practical tranexamic acid dosing scheme based on population pharmacokinetics in children undergoing cardiac surgery. Anesthesiology. 2013;118:853-862.
22. Wesley MC, Pereira LM, Scharp LA, Emani SM, McGowan FX Jr, DiNardo JA. Pharmacokinetics of tranexamic acid in neonates, infants, and children undergoing cardiac surgery with cardiopulmonary bypass. Anesthesiology. 2015;122:746-758.
23. Bagshaw SM, Peets AD, Hameed M, Boiteau PJ, Laupland KB, Doig CJ. Dialysis disequilibrium syndrome: brain death following hemodialysis for metabolic acidosis and acute renal failure-a case report. BMC Nephrol. 2004;5:9.
24. Patel N, Dalal P, Panesar M. Dialysis disequilibrium syndrome: a narrative review. Semin Dial. 2008;21:493-498.
25. Zepeda-Orozco D, Quigley R. Dialysis disequilibrium syndrome. Pediatr Nephrol. 2012;27:2205-2211.
26. Lecker I, Wang DS, Romaschin AD, Peterson M, Mazer CD, Orser BA. Tranexamic acid concentrations associated with human seizures inhibit glycine receptors. J Clin Invest. 2012;122:4654-4666.
27. Furtmüller R, Schlag MG, Berger M, et al. Tranexamic acid, a widely used antifibrinolytic agent, causes convulsions by a gamma-aminobutyric acid(A) receptor antagonistic effect. J Pharmacol Exp Ther. 2002;301:168-173.
28. Reinsfelt B, Ricksten SE, Zetterberg H, Blennow K, Fredén-Lindqvist J, Westerlind A. Cerebrospinal fluid markers of brain injury, inflammation, and blood-brain barrier dysfunction in cardiac surgery. Ann Thorac Surg. 2012;94:549-555.
29. Cavaglia M, Seshadri SG, Marchand JE, Ochocki CL, Mee RB, Bokesch PM. Increased transcription factor expression and permeability of the blood brain barrier associated with cardiopulmonary bypass in lambs. Ann Thorac Surg. 2004;78:1418-1425.
30. Schlag MG, Hopf R, Zifko U, Redl H. Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats. Acta Neurochir (Wien). 2002;144:63-69.
31. Hillis GS, Croal BL, Buchan KG, et al. Renal function and outcome from coronary artery bypass grafting: impact on mortality after a 2.3-year follow-up. Circulation. 2006;113:1056-1062.
32. Weerasinghe A, Hornick P, Smith P, Taylor K, Ratnatunga C. Coronary artery bypass grafting in non-dialysis-dependent mild-to-moderate renal dysfunction. J Thorac Cardiovasc Surg. 2001;121:1083-1089.
33. Rosner MH, Okusa MD. Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol. 2006;1:19-32.
34. Fiechtner BK, Nuttall GA, Johnson ME, et al. Plasma tranexamic acid concentrations during cardiopulmonary bypass. Anesth Analg. 2001;92:1131-1136.
35. Ng W, Jerath A, Wasowicz M. Tranexamic acid: a clinical review. Anesthesiol Intensive Ther. 2015;47:339-350.
36. Roberts I, Shakur H, Coats T, et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess. 2013;17:1-79.